TISIDB

Summary
Symbol	FOXO3
Name	forkhead box O3
Aliases	AF6q21; FOXO2; FKHRL1; FOXO3A; FKHRL1P2; FOXO2A; forkhead box O3A; forkhead homolog (rhabdomyosarcoma) like ......
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm, cytosol Nucleus Mitochondrion matrix Mitochondrion outer membrane Peripheral membrane protein Cytoplasmic side Note=Retention in the cytoplasm contributes to its inactivation (PubMed:10102273, PubMed:15084260, PubMed:16751106). Translocates to the nucleus upon oxidative stress and in the absence of survival factors (PubMed:10102273, PubMed:16751106). Translocates in a AMPK-dependent manner into the mitochondrion in response to metabolic stress (PubMed:23283301, PubMed:29445193).
Domain	PF00250 Forkhead domain PF16676 Transactivation domain of FOXO protein family PF16675 KIX-binding domain of forkhead box O
Function	Transcriptional activator which triggers apoptosis in the absence of survival factors, including neuronal cell death upon oxidative stress (PubMed:10102273, PubMed:16751106). Recognizes and binds to the DNA sequence 5'-[AG]TAAA[TC]A-3' (PubMed:21329882). Participates in post-transcriptional regulation of MYC: following phosphorylation by MAPKAPK5, promotes induction of miR-34b and miR-34c expression, 2 post-transcriptional regulators of MYC that bind to the 3'UTR of MYC transcript and prevent its translation (PubMed:21329882). In response to metabolic stress, translocates into the mitochondria where it promotes mtDNA transcription (PubMed:23283301).

> Gene Ontology [ TOP ]
Biological Process	GO:0000302 response to reactive oxygen species GO:0001541 ovarian follicle development GO:0001542 ovulation from ovarian follicle GO:0001544 initiation of primordial ovarian follicle growth GO:0001547 antral ovarian follicle growth GO:0001556 oocyte maturation GO:0001666 response to hypoxia GO:0001678 cellular glucose homeostasis GO:0002262 myeloid cell homeostasis GO:0006417 regulation of translation GO:0006979 response to oxidative stress GO:0007281 germ cell development GO:0007292 female gamete generation GO:0007548 sex differentiation GO:0007568 aging GO:0008406 gonad development GO:0008585 female gonad development GO:0009743 response to carbohydrate GO:0009746 response to hexose GO:0009749 response to glucose GO:0009991 response to extracellular stimulus GO:0009994 oocyte differentiation GO:0010035 response to inorganic substance GO:0010421 hydrogen peroxide-mediated programmed cell death GO:0010608 posttranscriptional regulation of gene expression GO:0010721 negative regulation of cell development GO:0016055 Wnt signaling pathway GO:0019827 stem cell population maintenance GO:0021700 developmental maturation GO:0022412 cellular process involved in reproduction in multicellular organism GO:0022602 ovulation cycle process GO:0030099 myeloid cell differentiation GO:0030111 regulation of Wnt signaling pathway GO:0030178 negative regulation of Wnt signaling pathway GO:0030218 erythrocyte differentiation GO:0030330 DNA damage response, signal transduction by p53 class mediator GO:0030728 ovulation GO:0031667 response to nutrient levels GO:0031960 response to corticosteroid GO:0032844 regulation of homeostatic process GO:0032846 positive regulation of homeostatic process GO:0033209 tumor necrosis factor-mediated signaling pathway GO:0033500 carbohydrate homeostasis GO:0034101 erythrocyte homeostasis GO:0034248 regulation of cellular amide metabolic process GO:0034284 response to monosaccharide GO:0034599 cellular response to oxidative stress GO:0034612 response to tumor necrosis factor GO:0034614 cellular response to reactive oxygen species GO:0035902 response to immobilization stress GO:0036293 response to decreased oxygen levels GO:0036294 cellular response to decreased oxygen levels GO:0036473 cell death in response to oxidative stress GO:0036474 cell death in response to hydrogen peroxide GO:0038034 signal transduction in absence of ligand GO:0042542 response to hydrogen peroxide GO:0042593 glucose homeostasis GO:0042698 ovulation cycle GO:0042770 signal transduction in response to DNA damage GO:0043523 regulation of neuron apoptotic process GO:0043525 positive regulation of neuron apoptotic process GO:0045137 development of primary sexual characteristics GO:0045637 regulation of myeloid cell differentiation GO:0045639 positive regulation of myeloid cell differentiation GO:0045646 regulation of erythrocyte differentiation GO:0045648 positive regulation of erythrocyte differentiation GO:0045665 negative regulation of neuron differentiation GO:0046545 development of primary female sexual characteristics GO:0046660 female sex differentiation GO:0048469 cell maturation GO:0048477 oogenesis GO:0048511 rhythmic process GO:0048545 response to steroid hormone GO:0048599 oocyte development GO:0048608 reproductive structure development GO:0048854 brain morphogenesis GO:0048872 homeostasis of number of cells GO:0050768 negative regulation of neurogenesis GO:0051384 response to glucocorticoid GO:0051385 response to mineralocorticoid GO:0051402 neuron apoptotic process GO:0051412 response to corticosterone GO:0051961 negative regulation of nervous system development GO:0060070 canonical Wnt signaling pathway GO:0060828 regulation of canonical Wnt signaling pathway GO:0061351 neural precursor cell proliferation GO:0061458 reproductive system development GO:0070301 cellular response to hydrogen peroxide GO:0070482 response to oxygen levels GO:0070997 neuron death GO:0071322 cellular response to carbohydrate stimulus GO:0071326 cellular response to monosaccharide stimulus GO:0071331 cellular response to hexose stimulus GO:0071333 cellular response to glucose stimulus GO:0071356 cellular response to tumor necrosis factor GO:0071383 cellular response to steroid hormone stimulus GO:0071384 cellular response to corticosteroid stimulus GO:0071385 cellular response to glucocorticoid stimulus GO:0071386 cellular response to corticosterone stimulus GO:0071389 cellular response to mineralocorticoid stimulus GO:0071396 cellular response to lipid GO:0071407 cellular response to organic cyclic compound GO:0071417 cellular response to organonitrogen compound GO:0071453 cellular response to oxygen levels GO:0071456 cellular response to hypoxia GO:0071548 response to dexamethasone GO:0072331 signal transduction by p53 class mediator GO:0072577 endothelial cell apoptotic process GO:0072593 reactive oxygen species metabolic process GO:0090090 negative regulation of canonical Wnt signaling pathway GO:0097150 neuronal stem cell population maintenance GO:0097191 extrinsic apoptotic signaling pathway GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand GO:0097468 programmed cell death in response to reactive oxygen species GO:0098727 maintenance of cell number GO:0198738 cell-cell signaling by wnt GO:1900407 regulation of cellular response to oxidative stress GO:1900409 positive regulation of cellular response to oxidative stress GO:1901031 regulation of response to reactive oxygen species GO:1901033 positive regulation of response to reactive oxygen species GO:1901214 regulation of neuron death GO:1901216 positive regulation of neuron death GO:1901298 regulation of hydrogen peroxide-mediated programmed cell death GO:1901300 positive regulation of hydrogen peroxide-mediated programmed cell death GO:1901652 response to peptide GO:1901653 cellular response to peptide GO:1901654 response to ketone GO:1901655 cellular response to ketone GO:1902882 regulation of response to oxidative stress GO:1902884 positive regulation of response to oxidative stress GO:1903201 regulation of oxidative stress-induced cell death GO:1903205 regulation of hydrogen peroxide-induced cell death GO:1903209 positive regulation of oxidative stress-induced cell death GO:1903409 reactive oxygen species biosynthetic process GO:1903426 regulation of reactive oxygen species biosynthetic process GO:1903428 positive regulation of reactive oxygen species biosynthetic process GO:1903706 regulation of hemopoiesis GO:1903708 positive regulation of hemopoiesis GO:1904019 epithelial cell apoptotic process GO:1904035 regulation of epithelial cell apoptotic process GO:1904037 positive regulation of epithelial cell apoptotic process GO:1904645 response to beta-amyloid GO:1904646 cellular response to beta-amyloid GO:1905206 positive regulation of hydrogen peroxide-induced cell death GO:1990089 response to nerve growth factor GO:1990090 cellular response to nerve growth factor stimulus GO:1990785 response to water-immersion restraint stress GO:2000177 regulation of neural precursor cell proliferation GO:2000351 regulation of endothelial cell apoptotic process GO:2000353 positive regulation of endothelial cell apoptotic process GO:2000377 regulation of reactive oxygen species metabolic process GO:2000379 positive regulation of reactive oxygen species metabolic process
Molecular Function	GO:0001047 core promoter binding GO:0001221 transcription cofactor binding GO:0001227 transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0003682 chromatin binding GO:0008013 beta-catenin binding GO:0008134 transcription factor binding GO:0031490 chromatin DNA binding GO:0043566 structure-specific DNA binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04062 Chemokine signaling pathway hsa04068 FoxO signaling pathway hsa04151 PI3K-Akt signaling pathway hsa04152 AMPK signaling pathway hsa04722 Neurotrophin signaling pathway hsa04917 Prolactin signaling pathway
Reactome	R-HSA-198693: AKT phosphorylates targets in the nucleus R-HSA-1280218: Adaptive Immune System R-HSA-5674400: Constitutive Signaling by AKT1 E17K in Cancer R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2172127: DAP12 interactions R-HSA-2424491: DAP12 signaling R-HSA-8862803: Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models R-HSA-1266738: Developmental Biology R-HSA-1643685: Disease R-HSA-5663202: Diseases of signal transduction R-HSA-186763: Downstream signal transduction R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR) R-HSA-2454202: Fc epsilon receptor (FCERI) signaling R-HSA-180292: GAB1 signalosome R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-6785807: Interleukin-4 and 13 signaling R-HSA-5683057: MAPK family signaling cascades R-HSA-5687128: MAPK6/MAPK4 signaling R-HSA-187037: NGF signalling via TRKA from the plasma membrane R-HSA-8863678: Neurodegenerative Diseases R-HSA-2219528: PI3K/AKT Signaling in Cancer R-HSA-198203: PI3K/AKT activation R-HSA-1257604: PIP3 activates AKT signaling R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization R-HSA-162582: Signal Transduction R-HSA-177929: Signaling by EGFR R-HSA-449147: Signaling by Interleukins R-HSA-1181150: Signaling by NODAL R-HSA-186797: Signaling by PDGF R-HSA-1433557: Signaling by SCF-KIT R-HSA-983705: Signaling by the B Cell Receptor (BCR) R-HSA-166520: Signalling by NGF

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04062 Chemokine signaling pathway
hsa04068 FoxO signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04152 AMPK signaling pathway
hsa04722 Neurotrophin signaling pathway
hsa04917 Prolactin signaling pathway

Reactome

R-HSA-198693: AKT phosphorylates targets in the nucleus
R-HSA-1280218: Adaptive Immune System
R-HSA-5674400: Constitutive Signaling by AKT1 E17K in Cancer
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-8862803: Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-180292: GAB1 signalosome
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5687128: MAPK6/MAPK4 signaling
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-8863678: Neurodegenerative Diseases
R-HSA-2219528: PI3K/AKT Signaling in Cancer
R-HSA-198203: PI3K/AKT activation
R-HSA-1257604: PIP3 activates AKT signaling
R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-449147: Signaling by Interleukins
R-HSA-1181150: Signaling by NODAL
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF

Summary
Symbol	FOXO3
Name	forkhead box O3
Aliases	AF6q21; FOXO2; FKHRL1; FOXO3A; FKHRL1P2; FOXO2A; forkhead box O3A; forkhead homolog (rhabdomyosarcoma) like ......
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between FOXO3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	FOXO3
Name	forkhead box O3
Aliases	AF6q21; FOXO2; FKHRL1; FOXO3A; FKHRL1P2; FOXO2A; forkhead box O3A; forkhead homolog (rhabdomyosarcoma) like ......
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of FOXO3 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.53	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	FOXO3
Name	forkhead box O3
Aliases	AF6q21; FOXO2; FKHRL1; FOXO3A; FKHRL1P2; FOXO2A; forkhead box O3A; forkhead homolog (rhabdomyosarcoma) like ......
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of FOXO3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.031	0.878
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.207	0.854
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.096	0.906
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.028	0.93
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.21	0.933
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.201	0.948
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.173	0.631
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.371	0.828
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.073	0.97
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.234	0.837
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.937	0.559
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.036	0.667

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of FOXO3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	0	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	0	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	3.7	-1.1	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	FOXO3
Name	forkhead box O3
Aliases	AF6q21; FOXO2; FKHRL1; FOXO3A; FKHRL1P2; FOXO2A; forkhead box O3A; forkhead homolog (rhabdomyosarcoma) like ......
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FOXO3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	FOXO3
Name	forkhead box O3
Aliases	AF6q21; FOXO2; FKHRL1; FOXO3A; FKHRL1P2; FOXO2A; forkhead box O3A; forkhead homolog (rhabdomyosarcoma) like ......
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FOXO3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FOXO3. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	FOXO3
Name	forkhead box O3
Aliases	AF6q21; FOXO2; FKHRL1; FOXO3A; FKHRL1P2; FOXO2A; forkhead box O3A; forkhead homolog (rhabdomyosarcoma) like ......
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FOXO3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	FOXO3
Name	forkhead box O3
Aliases	AF6q21; FOXO2; FKHRL1; FOXO3A; FKHRL1P2; FOXO2A; forkhead box O3A; forkhead homolog (rhabdomyosarcoma) like ......
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of FOXO3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	FOXO3
Name	forkhead box O3
Aliases	AF6q21; FOXO2; FKHRL1; FOXO3A; FKHRL1P2; FOXO2A; forkhead box O3A; forkhead homolog (rhabdomyosarcoma) like ......
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between FOXO3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	FOXO3
Name	forkhead box O3
Aliases	AF6q21; FOXO2; FKHRL1; FOXO3A; FKHRL1P2; FOXO2A; forkhead box O3A; forkhead homolog (rhabdomyosarcoma) like ......
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting FOXO3 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse FOXO3